THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, October 25, 2021
Celsion Corporation Adds Experienced professionals to its management to advance its PLACCINE DNA-mediated vaccine platform and Phase II GEN-1 immunotherapy study.
FREMONT, CA: Employees are a vital source of competitive advantage, thus attracting great people is critical to every company's success. You can enhance efficiency across your organization and provide the top-notch customer service required to drive profitability if you have the correct team in place. Celsion Corporation is reinforcing its management team with the addition of a new hire and promotion in its vaccine research program, as well as the employment of a seasoned clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Dr. Carlo Lavarone will oversee the PLACCINE vaccination initiative as the project leader. He will be stationed in Huntsville, Alabama, and has over 15 years of experience in vaccine research and development, including molecular target discovery and characterization of RNA vaccines. He was most recently a science advisor for both Guidepoint and Clora from 2019 to 2021, offering expertise for a viral target and RNA vaccine delivery technology. In 2015, Dr. Iavarone began working with GlaxoSmithKline as a senior scientist, researching small compounds and RNA vaccines in animal and human cell lines.
Dr. Subeena Sood, who is also based in Huntsville, is in charge of assay development and in vivo research for the PLACCINE DNA vaccine and gene therapy initiative. She has worked for several pharmaceutical businesses in experiment design, pharmacological and biochemical assays, manufacturing process design and development, and Quality by Design optimization and implementation. Dr. Sood joined Celsion in 2019 as the manager of animal research, where she is responsible for all preclinical research design and execution. Before joining Celsion, she worked at Novocol Healthcare as a Formulation Scientist II since 2017.
Beth J. Llewellyn will be stationed in Lawrenceville headquarters and will be in charge of the current Phase II OVATION 2 Study with GEN-1 in advanced ovarian cancer. She was previously the President of 2L Pharma, a clinical operations consulting firm she established in 2014. Her responsibilities included developing protocols for submissions to the US Food and Drug Administration for Investigational New Drugs, clinical trial site qualification and compliance, and serving as a liaison between clinical trial sites, contract research firms, and study sponsors.
“As we continue to advance the development of our PLACCINE DNA-mediated vaccine platform and or Phase II study of GEN-1, we are delighted to deepen our bench strength with these talented and experienced professionals,” said Michael H. Tardugno, Chairman, President and Chief Executive Officer of Celsion.
More in News